Terminology Service < Semantic Lookup Platform

All terms in NCIT

Label	Id	Description
Curcuma longa	NCIT_C73983
Larrea tridentata	NCIT_C73984
Upamostat	NCIT_C73985	[An orally bioavailable, 3-amidinophenylalanine-derived, second generation serine protease inhibitor prodrug targeting the human urokinase plasminogen activator (uPA) system with potential antineoplastic and antimetastatic activities. After oral administration, upamostat is converted to the active N alpha-(2,4,6-triisopropylphenylsulfonyl)-3-amidino-(L)-phenylalanine-4-ethoxycarbonylpiperazide (WX-UK1), which inhibits several serine proteases, particularly uPA; inhibition of uPA may result in the inhibition of tumor growth and metastasis. uPA is a serine protease involved in degradation of the extracellular matrix and tumor cell migration and proliferation.]
DC-OVA Vaccine	NCIT_C73986	[An autologous, multivalent dendritic cell vaccine targeting ovarian cancer with potential immunostimulating and antineoplastic activities. DC-OVA vaccine is produced in vitro by pulsing autologous dendritic cells with killed autologous primary ovarian tumors as a source of tumor-associated antigens (TAAs); the pulsed DCs are then matured using various cytokines. Upon administration, DC-OVA vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against ovarian cancer TAA-expressing ovarian cancer cells.]
Autologous Tumor Cell Vaccine	NCIT_C1980	[A therapeutic agent produced by isolating tumor cells from an individual and processing these tumor cells into a vaccine formulation in vitro; the vaccine is then administered to the individual from whom the tumor cells were isolated. Typically combined with an adjuvant immunostimulant, an autologous cell vaccine may elicit a cytotoxic T-lymphocytic immune response to cell surface-expressed tumor-associated antigens (TAAs), resulting in tumor cell death. (NCI04)]
Scutellaria lateriflora	NCIT_C73980
Symphytum officinale	NCIT_C73981
Sinapis alba	NCIT_C73982
JAK2 NM_004972.3:c.1849G>T	NCIT_C105910	[A nucleotide substitution at position 1849 of the coding sequence of the JAK2 gene where guanine has been mutated to thymine.]
JAK2 Gene Mutation	NCIT_C84255	[Mutation of the Janus 2 kinase gene at chromosome 9. It is seen in most patients with polycythemia vera and less frequently in other myeloproliferative neoplasms.]
JAK2 NP_004963.1:p.V617F	NCIT_C105908	[A change in the amino acid residue at position 617 in the tyrosine-protein kinase JAK2 protein where valine has been replaced by phenylalanine.]
JAK2 NM_004972.3:c.2792A>G	NCIT_C105911	[A nucleotide substitution at position 2792 of the coding sequence of the JAK2 gene where adenine has been mutated to guanine.]
JAK2 NP_004963.1:p.Y931C	NCIT_C105912	[A change in the amino acid residue at position 931 in the tyrosine-protein kinase JAK2 protein where tyrosine has been replaced by cysteine.]
JAK2 Protein Variant	NCIT_C105906	[A variation in the amino acid sequence for the tyrosine-protein kinase JAK2 protein.]
JAK2 NP_004963.1:p.E985K	NCIT_C105913	[A change in the amino acid residue at position 985 in the tyrosine-protein kinase JAK2 protein where glutamic acid has been replaced by lysine.]
JAK2 NP_004963.1:p.G935R	NCIT_C105914	[A change in the amino acid residue at position 935 in the tyrosine-protein kinase JAK2 protein where glycine has been replaced by arginine.]
JAK2 NP_004963.1:p.I960V	NCIT_C105915	[A change in the amino acid residue at position 960 in the tyrosine-protein kinase JAK2 protein where isoleucine has been replaced by valine.]
JAK2 NP_004963.1:p.M929I	NCIT_C105916	[A change in the amino acid residue at position 929 in the tyrosine-protein kinase JAK2 protein where methionine has been replaced by isoleucine.]
JAK2 NP_004963.1:p.R938L	NCIT_C105917	[A change in the amino acid residue at position 938 in the tyrosine-protein kinase JAK2 protein where arginine has been replaced by leucine.]
EPGN Gene	NCIT_C105918	[This gene plays a role in epithelial cell growth.]